SEATTLE--(BUSINESS WIRE)--Kestra Medical Technologies is launching the ASSURE Clinician Experience (ACE), a program that lets electrophysiology and cardiology professionals wear and simulate use of the ASSURE® Wearable Cardioverter Defibrillator (WCD) system at The Heart Rhythm Society #HRX2023 global health and technology conference, September 21-23, 2023 in Seattle, WA. Clinicians that participate will be measured, fit, and trained in the use of a demonstration ASSURE WCD System and experience everyday usage of the ASSURE system while participating in conference activities. Participants will be able to review their personal usage and rhythm data in the Kestra CareStation™ remote patient data platform.
“Wearable defibrillators (WCDs) work when patients wear them,” said Laura Gustavson, Vice President of Clinical Marketing. “There’s no better way of seeing how the ASSURE system has been designed for comfort and wearability than having WCD prescribers experience it for themselves. The latest updates to the ASSURE WCD system include an enhanced suite of capabilities, including heart rate histograms and trends, reporting on supraventricular tachycardia (SVT) episodes, and the ability for patient-triggered recording of heart rhythm episodes, so cardiology care teams can identify additional presenting arrythmias and further optimize patient care.”
The ASSURE WCD system represents the next generation of monitoring and therapy to protect patients at risk of sudden cardiac arrest. The system includes a wearable monitoring and defibrillation device that provides autonomous detection and defibrillation for ventricular arrhythmias, when needed. It is the first WCD designed and developed with specific options for female cardiac patients. The complete Cardiac Recovery System® platform includes the ASSURE WCD, the ASSURE patient app, the ASSURE Assist® service, and Kestra CareStation™ remote patient data platform, all working together to provide comfortable protection for patients and clear insights for their healthcare providers. The ASSURE WCD system has protected thousands of patients since being launched in 2021.
About Kestra Medical Technologies
Kestra Medical Technologies, Inc. is a privately held wearable medical device and digital healthcare company that protects cardiac patients with diagnostic monitoring and therapeutic technologies that are intuitive, intelligent, and mobile. Kestra was founded in 2014 by leaders from the external (AED) and internal (ICD) defibrillation industries. Based in Kirkland, Washington, Kestra is a portfolio company of Bain Capital, one of the world’s leading alternative investment firms with deep global experience in healthcare.
Forward-Looking Statements
Statements Kestra makes in this press release that relate to future plans, events, prospects, or performance are forward-looking statements and as such, are subject to a number of risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from the expectations expressed. While these current forward-looking statements represent the current beliefs of Management as of the date published, Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, Kestra undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances, or unanticipated events.
